Table 3.
Summary of Meta-Analysis Results of IC+CCRT versus CCRT.
| EBV-DNA Cutoff | Outcomes | No. of studies | Model | HR (95% CI) | p | Heterogeneity (I 2, p) |
|---|---|---|---|---|---|---|
| ≥4000 copies/ml | OS | 4 | Fixed | 0.70 (0.58-0.83) | 0.000 | 0.0%,0.794 |
| PFS | 3 | Fixed | 0.83 (0.70-0.99) | 0.033 | 0.0%, 0.778 | |
| DMFS | 4 | Fixed | 0.79 (0.69-0.90) | 0.000 | 0.0%, 0.997 | |
| LRFS | 2 | Fixed | 1.07 (0.80-1.42) | 0.647 | 0.0%, 0.697 | |
| <4000 copies/ml | OS | 3 | Fixed | 0.88(0.55-1.16) | 0.240 | 44.6%, 0.164 |
| PFS | 3 | Fixed | 0.98 (0.74-1.31) | 0.908 | 0.0%, 0.564 | |
| DMFS | 4 | Fixed | 0.57 (0.39-0.85) | 0.006 | 0.0%, 0.648 | |
| LRFS | 2 | Fixed | 0.98 (0.54-1.77) | 0.943 | 22.3%, 0.257 |
EBV-DNA, Epstein-Barr virus deoxyribonucleic acid; HR, hazard ratio; CI, confidence interval.